ACTIVITY OVERVIEW | This CME-certified Webcast contains video and downloadable slides from the symposium, Evaluating Emerging Targeted Therapies in the Management of Metastatic Colorectal Cancer, a prIME Oncology educational activity that was held on 9 November 2011 in New York, New York. |
FACULTY | John Marshall, MD
Georgetown University
Lombardi Comprehensive
Cancer Center
Washington, DC
Edith Mitchell, MD, FACP
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania |
TARGET AUDIENCE | This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with metastatic colorectal cancer (CRC). |
|
|
 |
|
Expert Discussion
|
 |
|
Downloadable Slides
|
|
 |
TOPICS | New options for targeting angiogenesis: An assessment of recent data
Edith Mitchell, MD, FACP
Beyond angiogenesis: Updates on agents of interest
John Marshall, MD
|
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Evaluate recently reported clinical data surrounding the use of novel antiangiogenic strategies in the management of metastatic colorectal cancer
- Identify novel nonantiangiogenic molecularly targeted agents, and discuss their clinical development status
|
Disclosures | Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Marshall has disclosed that he has received consulting fees from Genentech and Amgen. He has also performed contracted research for Genentech and Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Mitchell has disclosed that she has received consulting fees from Sanofi. She has also received salary from Thomas Jefferson University. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Amy Furedy, RN, OCN (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Heather Tomlinson, MA (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
|
Scroll down to review the CME INFO and view the activity
|
Release Date
|
12/23/2011
|
|
Expiration Date
|
12/23/2012
|
SPONSORSHIP | This activity is sponsored by prIME Oncology
|
SUPPORT | This CME activity is supported by an educational grant from
Sanofi-aventis U.S., Inc.
and
 |
Continuing Education Statement | rIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME ®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
